Stelara vs Skyrizi
Ustekinumab vs Risankizumab · Comparison Guide
Quick Comparison
| Feature | Stelara | Skyrizi |
|---|---|---|
| Generic Name | Ustekinumab | Risankizumab |
| Manufacturer | Janssen | AbbVie |
| Drug Class | IL-12/23 Inhibitor | IL-23 Inhibitor |
| Shared Conditions | Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis | |
Key Differences: Stelara vs Skyrizi
Both target IL-23 but Stelara also blocks IL-12 while Skyrizi selectively targets only IL-23's p19 subunit. For Crohn's disease, a head-to-head comparison (SEQUENCE trial) showed Skyrizi superior to Stelara on some endpoints. For psoriasis, Skyrizi has shown higher PASI 100 clearance rates. Stelara has more biosimilars available and a longer track record. Skyrizi requires less frequent dosing for psoriasis (every 12 weeks vs 12 weeks, both similar) but every 8 weeks for Crohn's maintenance.
💊 Stelara (Ustekinumab)
- Class: IL-12/23 Inhibitor
- Manufacturer: Janssen
- Full Stelara information →
💊 Skyrizi (Risankizumab)
- Class: IL-23 Inhibitor
- Manufacturer: AbbVie
- Full Skyrizi information →
Both target IL-23 but Stelara also blocks IL-12 while Skyrizi selectively targets only IL-23's p19 subunit. For Crohn's disease, a head-to-head comparison (SEQUENCE trial) showed Skyrizi superior to Stelara on some endpoints. For psoriasis, Skyrizi has shown higher PASI 100 clearance rates. Stelara has more biosimilars available and a longer track record. Skyrizi requires less frequent dosing for psoriasis (every 12 weeks vs 12 weeks, both similar) but every 8 weeks for Crohn's maintenance.
Neither Stelara nor Skyrizi is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Stelara and Skyrizi are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Stelara and Skyrizi both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Stelara and Skyrizi
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Stelara and Skyrizi should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.